Search

Bruck Kifle

Examiner (ID: 6836, Phone: (571)272-0668 , Office: P/1624 )

Most Active Art Unit
1624
Art Unit(s)
1624, 1611, 1622, 1202
Total Applications
3432
Issued Applications
2601
Pending Applications
218
Abandoned Applications
651

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16253473 [patent_doc_number] => 20200262847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 16/867835 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867835 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/867835
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same May 5, 2020 Issued
Array ( [id] => 16238206 [patent_doc_number] => 20200255440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => ETHYNYL DERIVATIVES [patent_app_type] => utility [patent_app_number] => 16/865233 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16865233 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/865233
Ethynyl derivatives Apr 30, 2020 Issued
Array ( [id] => 16970404 [patent_doc_number] => 11066364 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-20 [patent_title] => NLRX1 ligands [patent_app_type] => utility [patent_app_number] => 16/864717 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 65 [patent_no_of_words] => 23096 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864717 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/864717
NLRX1 ligands Apr 30, 2020 Issued
Array ( [id] => 16421869 [patent_doc_number] => 20200347067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => TRICYCLIC AMINE COMPOUNDS AS CDK2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/863770 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 5325 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863770 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/863770
Tricyclic amine compounds as CDK2 inhibitors Apr 29, 2020 Issued
Array ( [id] => 19910204 [patent_doc_number] => 12286400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-29 [patent_title] => Isofagomine salts, methods of use and formulations [patent_app_type] => utility [patent_app_number] => 17/605979 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 20503 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605979 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/605979
Isofagomine salts, methods of use and formulations Apr 23, 2020 Issued
Array ( [id] => 16390929 [patent_doc_number] => 20200331870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => MCL-1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/857021 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97713 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857021 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/857021
MCL-1 inhibitors Apr 22, 2020 Issued
Array ( [id] => 17702814 [patent_doc_number] => 20220202820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS [patent_app_type] => utility [patent_app_number] => 17/604109 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6184 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604109 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/604109
USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS Apr 14, 2020 Abandoned
Array ( [id] => 16398684 [patent_doc_number] => 20200339542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/847975 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847975 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/847975
AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS Apr 13, 2020 Abandoned
Array ( [id] => 17655311 [patent_doc_number] => 20220175776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS [patent_app_type] => utility [patent_app_number] => 17/602355 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602355 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/602355
COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS Apr 7, 2020 Abandoned
Array ( [id] => 16704318 [patent_doc_number] => 10954238 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-03-23 [patent_title] => Substituted naphthyridinone compounds useful as T cell activators [patent_app_type] => utility [patent_app_number] => 16/843024 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 183608 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843024 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/843024
Substituted naphthyridinone compounds useful as T cell activators Apr 7, 2020 Issued
Array ( [id] => 17734645 [patent_doc_number] => 20220220104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/600900 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600900 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/600900
Pyrazolopyridine compound as RET inhibitor and application thereof Apr 2, 2020 Issued
Array ( [id] => 16444845 [patent_doc_number] => 10836757 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-11-17 [patent_title] => Polymorphic forms of metopimazine [patent_app_type] => utility [patent_app_number] => 16/838402 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 24428 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838402 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/838402
Polymorphic forms of metopimazine Apr 1, 2020 Issued
Array ( [id] => 16799107 [patent_doc_number] => 10994023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Pyrrolobenzodiazepines and conjugates thereof [patent_app_type] => utility [patent_app_number] => 16/837336 [patent_app_country] => US [patent_app_date] => 2020-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 37993 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837336 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/837336
Pyrrolobenzodiazepines and conjugates thereof Mar 31, 2020 Issued
Array ( [id] => 17953466 [patent_doc_number] => 11479557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Inhibitors of the menin-MLL interaction [patent_app_type] => utility [patent_app_number] => 16/837421 [patent_app_country] => US [patent_app_date] => 2020-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 23 [patent_no_of_words] => 74236 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837421 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/837421
Inhibitors of the menin-MLL interaction Mar 31, 2020 Issued
Array ( [id] => 16343478 [patent_doc_number] => 20200308128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/835102 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835102 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/835102
MYC G-quadruplex stabilizing small molecules and their use Mar 29, 2020 Issued
Array ( [id] => 19931701 [patent_doc_number] => 12304898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Quinolyl-containing compound and pharmaceutical composition, and use thereof [patent_app_type] => utility [patent_app_number] => 17/594039 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14942 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 488 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594039 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/594039
Quinolyl-containing compound and pharmaceutical composition, and use thereof Mar 29, 2020 Issued
Array ( [id] => 16769806 [patent_doc_number] => 10980889 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-04-20 [patent_title] => C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors [patent_app_type] => utility [patent_app_number] => 16/831579 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68872 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16831579 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/831579
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Mar 25, 2020 Issued
Array ( [id] => 17889833 [patent_doc_number] => 11452780 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Mtorc1 inhibitors [patent_app_type] => utility [patent_app_number] => 16/828774 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 22 [patent_no_of_words] => 58057 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 701 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828774 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/828774
Mtorc1 inhibitors Mar 23, 2020 Issued
Array ( [id] => 17844855 [patent_doc_number] => 11434207 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => P2X4 receptor antagonist [patent_app_type] => utility [patent_app_number] => 16/826877 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40493 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 1397 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826877 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/826877
P2X4 receptor antagonist Mar 22, 2020 Issued
Array ( [id] => 17670877 [patent_doc_number] => 20220184044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => USE OF RIFAXIMIN ON CIRCULATING AGED NEUTROPHILS IN SICKLE CELL DISEASE [patent_app_type] => utility [patent_app_number] => 17/441840 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441840 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/441840
Use of rifaximin on circulating aged neutrophils in sickle cell disease Mar 22, 2020 Issued
Menu